Geron Corporation

Geron Corporation is a biotechnology company headquartered in Foster City, California, focused on the development and commercialization of therapeutic products for blood cancers and myeloid hematologic malignancies. The company's mission is to change lives by changing the course of blood cancer, aiming to develop therapeutics that meaningfully improve and extend the lives of individuals with life-threatening and debilitating diseases.

Geron's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor. This drug is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia. Imetelstat works by inhibiting telomerase activity in malignant stem and progenitor cells, and is also undergoing Phase 3 clinical trials for JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and other hematologic malignancies.

As a commercial-stage biopharmaceutical company, Geron reported RYTELO net product revenue of $183.6 million for the full year 2025, with projected revenues of $220 million to $240 million for 2026. Harout Semerjian serves as the President and CEO, and the company has recently undergone executive leadership transitions to align with its strategic priorities, including new appointments for Chief Legal Officer and Chief Commercial Officer. Geron maintains a market capitalization of approximately $961 million as of April 2026 and is noted for its strong financial health, holding more cash than debt on its balance sheet.